BidaskClub lowered shares of Regenxbio (NASDAQ:RGNX) from a hold rating to a sell rating in a research note released on Thursday, BidAskClub reports.
RGNX has been the subject of several other research reports. Zacks Investment Research upgraded Regenxbio from a sell rating to a hold rating in a research note on Thursday, July 25th. Chardan Capital reiterated a buy rating and set a $150.00 price objective (up from $145.00) on shares of Regenxbio in a research note on Tuesday, June 18th. TheStreet lowered Regenxbio from a c rating to a d+ rating in a research note on Thursday, May 9th. ValuEngine lowered Regenxbio from a strong-buy rating to a buy rating in a research note on Friday, May 10th. Finally, Morgan Stanley set a $84.00 price objective on Regenxbio and gave the stock a buy rating in a research note on Monday, July 15th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of Buy and an average target price of $81.41.
Shares of Regenxbio stock traded down $2.24 on Thursday, hitting $41.21. The company’s stock had a trading volume of 685,176 shares, compared to its average volume of 508,202. The company has a quick ratio of 14.21, a current ratio of 14.21 and a debt-to-equity ratio of 0.01. Regenxbio has a 1 year low of $38.56 and a 1 year high of $83.45. The firm’s fifty day moving average is $48.86. The firm has a market cap of $1.59 billion, a P/E ratio of 17.32 and a beta of 0.71.
Regenxbio (NASDAQ:RGNX) last announced its quarterly earnings results on Tuesday, May 7th. The biotechnology company reported ($0.89) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.85) by ($0.04). Regenxbio had a negative net margin of 41.99% and a negative return on equity of 9.90%. The business had revenue of $0.88 million during the quarter. As a group, equities analysts forecast that Regenxbio will post -2.4 earnings per share for the current fiscal year.
In other news, insider Kenneth T. Mills sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, May 20th. The stock was sold at an average price of $42.99, for a total transaction of $644,850.00. Following the transaction, the insider now directly owns 261,000 shares in the company, valued at approximately $11,220,390. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, SVP Curran Simpson sold 18,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 28th. The stock was sold at an average price of $50.00, for a total value of $900,000.00. Following the transaction, the senior vice president now owns 57,500 shares in the company, valued at $2,875,000. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 73,000 shares of company stock valued at $3,590,400. 13.80% of the stock is owned by company insiders.
Institutional investors have recently modified their holdings of the company. Municipal Employees Retirement System of Michigan acquired a new position in shares of Regenxbio during the 4th quarter worth approximately $357,000. Principal Financial Group Inc. boosted its holdings in shares of Regenxbio by 0.9% during the 4th quarter. Principal Financial Group Inc. now owns 249,625 shares of the biotechnology company’s stock worth $10,472,000 after purchasing an additional 2,124 shares during the last quarter. Raymond James & Associates boosted its holdings in shares of Regenxbio by 119.5% during the 1st quarter. Raymond James & Associates now owns 37,952 shares of the biotechnology company’s stock worth $2,175,000 after purchasing an additional 20,664 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Regenxbio by 11.9% during the 4th quarter. Geode Capital Management LLC now owns 378,788 shares of the biotechnology company’s stock worth $15,889,000 after purchasing an additional 40,159 shares during the last quarter. Finally, Amalgamated Bank acquired a new position in shares of Regenxbio during the 4th quarter worth approximately $208,000. Institutional investors and hedge funds own 81.38% of the company’s stock.
Regenxbio Company Profile
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform.
Featured Story: Book Value Per Share in Stock Trading
Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.